Has Alan Rauba, MD received payments from drug or device companies?

Yes. Drug and device makers reported $593,720 in general payments to Alan Rauba, MD across 1,562 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alan Rauba, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alan Rauba, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alan Rauba, MD

Endocrinology, Diabetes & Metabolism · Jefferson City, MONPI 1568442267

Payments from drug & device makers

$593,720in general payments, 2019–2025

Across 1,562 payments — averaging $380.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$291K
Novo Nordisk$213K
AstraZeneca$70K
Boehringer Ingelheim$14K
Tandem Diabetes Care, Inc.$2K
Amgen$876
plus $4K from 47 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	670	$290,628
Novo Nordisk	358	$212,682
AstraZeneca	90	$69,618
Boehringer Ingelheim	66	$13,758
Tandem Diabetes Care, Inc.	6	$1,811
Amgen(2 entities)	68	$876
Bayer	40	$495
AbbVie(2 entities)	29	$413
Abbott	29	$350
Radius Health, Inc.	20	$301
Sanofi-aventis U.S. LLC	21	$296
Amarin Pharma, Inc.	19	$282
Esperion Therapeutics, Inc.	13	$209
GSK	14	$208
Dexcom, Inc.	22	$190
Novartis	7	$141
Clarus Therapeutics Inc.	9	$123
Antares Pharma, Inc.	8	$115
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$107
Corcept Therapeutics	6	$98
Xeris Pharmaceuticals, Inc.	6	$96
Medtronic(2 entities)	5	$80
Johnson & Johnson(2 entities)	5	$70
Acella Pharmaceuticals, LLC	3	$57
IBSA Pharma Inc.	2	$50
Amneal Pharmaceuticals LLC	3	$48
Ascendis Pharma Endocrinology Inc	2	$46
Tolmar, Inc.	2	$35
Mannkind Corporation	2	$35
UCB, Inc.	1	$35
Pfizer	2	$30
Regeneron Healthcare Solutions, Inc.	2	$29
Insulet Corporation	2	$29
Vertex	1	$28
GE HealthCare	1	$28
Kowa Pharmaceuticals America, Inc.	2	$28
Currax Pharmaceuticals LLC	2	$25
Shire North American Group Inc	2	$24
ADMA Biomanufacturing LLC	1	$21
Averitas Pharma Inc.	1	$21
Cequr Corporation	1	$21
Aytu Biopharma, Inc.	1	$21
Lifescan, Inc.	1	$17
Recordati_rare_diseases_inc.	1	$17
Daiichi Sankyo Inc.	1	$16
Sanofi Pasteur Inc.	1	$16
Nevro Corp.	1	$16
Rhythm Pharmaceuticals, Inc.	1	$15
Melinta Therapeutics, LLC	1	$13
Kyowa Kirin, Inc.	1	$13
Merck	1	$12
OPKO Pharmaceuticals, LLC	1	$12
Phathom Pharmaceuticals, Inc.	1	$11

How this compares

$593,720 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri →

Medicare billing

Part B allowed, 2024

$161,975

Medicare patients

503

Services billed

5,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jefferson City

Christopher CaseJefferson City$692K
Ralph DudaSpringfield$3M
Thomas NickolasSaint Louis$945K
Anne GoldbergSaint Louis$830K
Janet McGillSaint Louis$828K
Gregory LedgerSpringfield$690K
Karen Chang-ChenChesterfield$640K
Julie SilversteinSaint Louis$536K
Ralph OiknineChesterfield$414K
Mariana TouzaNorth Kansas City$384K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →